Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

Pacak, Karel; Taieb, David

Birkhauser Verlag AG

07/2018

484

Mole

Inglês

9783319834269

15 a 20 dias

759

Descrição não disponível.
Classification of neuroendocrine tumors.- Molecular genetics of Pheochromocytoma and paraganglioma.- Molecular Genetics of MEN1-related Neuroendocrine Tumors.- Molecular genetics of MEN2-related neuroendocrine tumors.- Molecular genetics of Neuroblastoma.- Molecular Genetics of Gastroenteropancreatic Neuroendocrine Tumors.- Current and future radiopharmaceuticals in neuroendocrine tumors imaging.- SPECT/CT, PET/CT and PET/MR: Principles.- Internal dosimetry: Principles and Applications to NET.- Principles and Application of Molecular Imaging for Personalised Medicine and Guiding Interventions in Neuroendocrine Tumors.- Tumor metabolism and metabolomics of pheochromocytomas and paragangliomas.- Radionuclide imaging of pheochromocytoma and paraganglioma in the era of multi-omics.- Radionuclide imaging of Head and neck PGLs.- Radionuclide imaging of Chromaffin cell tumors.- Radionuclide imaging of Gastrointestinal neuroendocrine tumors.- Radionuclide imaging of Pancreatic neuroendocrine tumors.- Radionuclide imaging of Pulmonary, thymic neuroendocrine tumors and other neuroendocrine tumors.- Radionuclide imaging of Medullary thyroid carcinoma.- 131I-MIBG therapy for pheochromocytoma/paraganglioma and neuroblastoma.- Somatostatin receptors-based radionuclide therapy.- Alpha radionuclide therapy: Principles and Applications to NET.- Nanoparticles for Radionuclide Imaging and Therapy: Principles.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Carcinoid tumor;Chromaffin cell tumor;Neuroendocrine tumor;Radionuclide imaging;Radionuclide therapy;Pheochromocytoma;Paraganglioma;MEN1-related tumor;MEN2-related tumor;Neuroblastoma;Gastroenteropancreatic tumor;Internal dosimetry;Medullary thyroid carcinoma;131I-MIBG therapy;Nanoparticles